A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic

IF 13 1区医学 Q1 CLINICAL NEUROLOGY

Alzheimer's & Dementia Pub Date : 2025-02-25 DOI:10.1002/alz.14609

Federica Anastasi, Aida Fernández-Lebrero, Nicholas J. Ashton, Paula Ortiz-Romero, Javier Torres-Torronteras, Armand González-Escalante, Marta Milà-Alomà, José Contador, Greta García-Escobar, Rosa María Manero-Borràs, Irene Navalpotro-Gómez, Esther Jiménez-Moyano, Aparna Sahajan, Qinyu Hao, Bingqing Zhang, Andreas Jeromin, Nathalie Le Bastard, Alicia Nadal, Tahmine Mousavi, Gwendlyn Kollmorgen, Margherita Carboni, Oriol Grau-Rivera, Henrik Zetterberg, Marta del Campo, Kaj Blennow, Albert Puig-Pijoan, Marc Suárez-Calvet

{"title":"A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic","authors":"Federica Anastasi, Aida Fernández-Lebrero, Nicholas J. Ashton, Paula Ortiz-Romero, Javier Torres-Torronteras, Armand González-Escalante, Marta Milà-Alomà, José Contador, Greta García-Escobar, Rosa María Manero-Borràs, Irene Navalpotro-Gómez, Esther Jiménez-Moyano, Aparna Sahajan, Qinyu Hao, Bingqing Zhang, Andreas Jeromin, Nathalie Le Bastard, Alicia Nadal, Tahmine Mousavi, Gwendlyn Kollmorgen, Margherita Carboni, Oriol Grau-Rivera, Henrik Zetterberg, Marta del Campo, Kaj Blennow, Albert Puig-Pijoan, Marc Suárez-Calvet","doi":"10.1002/alz.14609","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>Blood-based biomarkers for Alzheimer's disease (AD) have been widely studied, but direct comparisons of several biomarkers in clinical settings remain limited.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>In this cross-sectional study, plasma biomarkers from 197 participants in the BIODEGMAR cohort (Hospital del Mar, Barcelona) were analyzed. Participants were classified based on AD cerebrospinal fluid (CSF) core biomarkers. We assessed the ability of plasma p-tau181, p-tau217, p-tau231, t-tau, and Aβ42/40 to classify Aβ pathology status.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>Plasma p-tau biomarkers had a greater diagnostic performance and larger effect sizes compared to t-tau and Aβ42/40 assays in detecting Aβ pathology. Among them, plasma p-tau217 consistently outperformed the others, demonstrating superior area under the curves. Furthermore, p-tau217 showed the strongest correlation between plasma and CSF levels, underscoring its potential as a reliable surrogate for CSF biomarkers.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>Several plasma biomarkers, targeting different epitopes and using different platforms, demonstrated high performance in detecting AD in a memory clinic setting.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Plasma p-tau biomarkers demonstrated higher diagnostic performance and larger effect sizes than t-tau and Aβ42/40 assays in detecting Alzheimer's disease.</li>\n \n <li>Among the p-tau biomarkers, p-tau217 assays consistently outperformed the others, providing superior classification of Aβ pathology status across different phosphorylation sites.</li>\n \n <li>p-tau217 assays showed the strongest correlation between plasma and CSF levels, indicating its potential as a reliable surrogate for CSF biomarkers.</li>\n \n <li>Several plasma p-tau biomarkers can be used in a specialized memory clinic to accurately detect Alzheimer's disease.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 2","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.14609","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/alz.14609","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

INTRODUCTION

Blood-based biomarkers for Alzheimer's disease (AD) have been widely studied, but direct comparisons of several biomarkers in clinical settings remain limited.

METHODS

In this cross-sectional study, plasma biomarkers from 197 participants in the BIODEGMAR cohort (Hospital del Mar, Barcelona) were analyzed. Participants were classified based on AD cerebrospinal fluid (CSF) core biomarkers. We assessed the ability of plasma p-tau181, p-tau217, p-tau231, t-tau, and Aβ42/40 to classify Aβ pathology status.

RESULTS

Plasma p-tau biomarkers had a greater diagnostic performance and larger effect sizes compared to t-tau and Aβ42/40 assays in detecting Aβ pathology. Among them, plasma p-tau217 consistently outperformed the others, demonstrating superior area under the curves. Furthermore, p-tau217 showed the strongest correlation between plasma and CSF levels, underscoring its potential as a reliable surrogate for CSF biomarkers.

DISCUSSION

Several plasma biomarkers, targeting different epitopes and using different platforms, demonstrated high performance in detecting AD in a memory clinic setting.

Highlights

Plasma p-tau biomarkers demonstrated higher diagnostic performance and larger effect sizes than t-tau and Aβ42/40 assays in detecting Alzheimer's disease.
Among the p-tau biomarkers, p-tau217 assays consistently outperformed the others, providing superior classification of Aβ pathology status across different phosphorylation sites.
p-tau217 assays showed the strongest correlation between plasma and CSF levels, indicating its potential as a reliable surrogate for CSF biomarkers.
Several plasma p-tau biomarkers can be used in a specialized memory clinic to accurately detect Alzheimer's disease.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer's & Dementia 医学-临床神经学

CiteScore

14.50

自引率

5.00%

发文量

299

审稿时长

3 months

期刊介绍： Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.